Compare Danaher Corporation (DHR) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nuscale Power Corporation — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Danaher Corporation is far larger — about 51× Nuscale Power Corporation's market cap, and Danaher Corporation pays a 0.74% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Nuscale Power Corporation for 29 Days on average.
| DHR | SMR | |
|---|---|---|
Market Cap | $152.87B | $3.00B |
Volume | 5,228,698 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $242.05 | $53.43 |
52-Week Low | $161.91 | $7.32 |
Typical Hold Time | 69 Days | 29 Days |
Enterprise Value | $175.08B | $1.93B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
NuScale Power (SMR) trades at $7.20, down 6.13% with bearish technical signals. The company shows concerning fundamentals with negative net income margins (-3,888.7% in 2026) despite analyst consensus of $11.25 price target. Recent news highlights ongoing investor investigations and competitive pressures in the nuclear energy sector.
While analysts maintain 50% buy ratings, significant operational losses and cash burn create substantial risk. The stock faces headwinds from execution challenges and dilution concerns, though long-term nuclear energy adoption trends provide potential upside for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
